Stock HLS HLS THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

News HLS Therapeutics Inc.

Equities

HLS

CA40390B1094

Market Closed - Toronto S.E.
Other stock markets
 14:59:56 2024-04-30 EDT 		5-day change 1st Jan Change
4.65 CAD -.--% Intraday chart for HLS Therapeutics Inc. -2.11% +17.72%
04-08 HLS Therapeutics Inc. Announces Reduce-IT Analysis Results Relating the Effects of VASCEPA CI
03-14 Transcript : HLS Therapeutics Inc., Q4 2023 Earnings Call, Mar 14, 2024

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
HLS Therapeutics to Host Q1 Fiscal 2024 Financial Results Conference Call
AQ
HLS Therapeutics to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
AQ
HLS Therapeutics Inc. Announces Reduce-IT Analysis Results Relating the Effects of VASCEPA
CI
New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups
AQ
Transcript : HLS Therapeutics Inc., Q4 2023 Earnings Call, Mar 14, 2024
HLS Therapeutics Reports Q4 2023 Net Loss of US$5.4 Million; Provides 2024 Outlook, Credit Agreement Update
MT
HLS Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
HLS Therapeutics Brief: Q4 2023 and fiscal 2023 product sales in Canada increased 11% and 10%, respectively, in CAD, compared to same periods in 2022
MT
HLS Therapeutics Brief: Q4 2023 revenue was US$15.9 million, Adjusted EBITDA was $5.3 million and cash from operations was $3.7 million
MT
HLS Therapeutics Announces Fiscal 2023 Financial Results
AQ
HLS Therapeutics Inc. Provides Consolidated Earnings Guidance for the Fiscal Year 2024
CI
HLS Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
HLS Therapeutics to Host Q4 and Fiscal 2023 Financial Results Conference Call
AQ
HLS Announces that Vascepa is now reimbursed by British Columbia's Provincial Drug Plan
AQ
HLS Therapeutics Says Vascepa Now Reimbursed by British Columbia's Provincial Drug Plan
MT
HLS Therapeutics Brief: Announcing that Vascepa is now reimbursed by British Columbia's Provincial Drug Plan
MT
HLS Announces that Vascepa® is now reimbursed by British Columbia's Provincial Drug Plan
AQ
HLS Therapeutics Inc. Announces CFO Changes
CI
HLS Therapeutics Announcing CFO Departure; John Hanna appointed Interim CFO to replace departing CFO Tim Hendrickson
MT
HLS Therapeutics Brief: Announcing CFO Departure; John Hanna appointed Interim CFO to replace departing CFO Tim Hendrickson
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. HLS Stock
  4. News HLS Therapeutics Inc.